scispace - formally typeset
C

Christian Junghanss

Researcher at University of Rostock

Publications -  175
Citations -  3011

Christian Junghanss is an academic researcher from University of Rostock. The author has contributed to research in topics: Transplantation & Medicine. The author has an hindex of 20, co-authored 144 publications receiving 2514 citations.

Papers
More filters
Journal ArticleDOI

Polymorphism nt7778G/T In Mitochondrial ATP8 Gene Promotes Protective Effect On Reactive Oxygen Species Level In Murine Hematopoietic Cells During Aging

TL;DR: Compared two conplastic mouse strains differing in one point mutation in the mtDNA affecting the respiratory chain, bone marrow cell composition of both strains showed an increase of hematopoietic stem cells (LSK cells: lineage-, sca-1+, c-kit+) and a significant increase in ATP levels during experimental time span from 3 to 24 months.
Journal ArticleDOI

Small but effective: trophoblast-derived miRNAs transported via exosomes as guardians against viral infections

TL;DR: Findings indicate a pivotal role of C19MC miRNAs in pregnancy by counteracting embryonal and fetal infections and, simultaneously, raise several further questions, including therapeutic approaches.
Journal ArticleDOI

Engraftment Effects of Intra Bone Marrow Compared to Intravenous Transplantation of Allogeneic Hematopoietic Stem Cells Following a Reduced Intensity Conditioning in a DLA-Identical Canine Littermate Model

TL;DR: Examining the feasibility and efficiency of IBM allogeneic HSCT in comparison to IV HS CT in dog leukocyte antigen (DLA) identical canine littermates using a RIC regimen and results demonstrated faster engraftment with an IBM HSCT approach compared to intravenous (IV) HSCT following myeloablative conditioning found it feasible.
Journal ArticleDOI

Evaluation of the Synergistic Potential of Simultaneous Pan- or Isoform-Specific BET and SYK Inhibition in B-Cell Lymphoma: An In Vitro Approach

TL;DR: The simultaneous inhibition of SYK and BET showed enhanced anti-proliferative effects, as well as inducing a distinct combination-specific gene expression profile, suggesting SYk and BET inhibition as a promising combination in the treatment of B-cell lymphoma.